Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

CompletedOBSERVATIONAL

Enrollment

333,580

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin

drug

DRUG

DPP-4 inhibitors

drug

Trial Locations (1)

RTI health solutions, One Or Multiple Sites